Notice NOT-HD-20-046 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-045 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-092 from the NIH Guide for Grants and Contracts. The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Notice NOT-CA-21-026 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-EY-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-004 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-018 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-316 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

Notice NOT-MH-21-110 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-138 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-137 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-135 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-075 from the NIH Guide for Grants and Contracts

Notice NOT-HS-21-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-107 from the NIH Guide for Grants and Contracts. The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

Notice NOT-TR-21-014 from the NIH Guide for Grants and Contracts

Notice NOT-TR-21-013 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-044 from the NIH Guide for Grants and Contracts

Notice NOT-TR-21-011 from the NIH Guide for Grants and Contracts